OBJECTIVE: To investigate the role of neuronal nitric oxide synthase (NOS1) in murine polymicrobial peritonitis and sepsis. DESIGN: Randomized experimental trial. SETTING: Animal research facility. SUBJECTS: B6129S NOS1+/+ and B6;129S4 NOS-/- mice. INTERVENTIONS: NOS1+/+ and NOS1-/- animals underwent cecal ligation and puncture (CLP) or sham surgery and received the NOS1 inhibitor 7-nitroindazole (7-NI) or vehicle. MEASUREMENTS AND MAIN RESULTS: After CLP, genetic deficiency and pharmacologic inhibition of NOS1 significantly increased risk of mortality [8.69 (3.27, 23.1), p<0.0001 and 1.71 (1.00, 2.92) p=0.05, hazard ratio of death (95% confidence interval) for NOS1-/- and 7-NI-treated NOS1+/+ respectively] compared with NOS1+/+ animals. In 7-NI-treated NOS1+/+ animals, there were increases (6 h) and then decreases (24 h), whereas in NOS-/- animals persistent increases in blood bacteria counts (p=0.04 for differing effects of 7-NI and NOS1-/-) were seen compared with NOS1(+/+) animals. After CLP, NOS1(-/-) had upregulation of inducible NOS and proinflammatory cytokines and greater increases in serum tumor necrosis factor-alpha and interleukin-6 levels compared with NOS1+/+ mice (all p<0.05). Following CLP, there were similar significant decreases in circulating leukocytes and lung lavage cells (p<or=0.0008) and significant increases in peritoneal lavage cells (p=0.0045) in all groups. Over 6 h and 24 h following CLP, compared with NOS1+/+, NOS-/- mice had significantly higher peritoneal cell concentrations {respectively 0.40+/-0.09 vs 0.79+/-0.15 [log(x10(4)cells/ml)] averaged over both times p=0.038}. CONCLUSIONS: Deficiency and inhibition of NOS1 increases mortality, possibly by increasing proinflammatory cytokine response and impairing bacterial clearance after CLP. These data suggest that NOS1 is important for survival, bacterial clearance, and regulation of cytokine response during infection and sepsis.
OBJECTIVE: To investigate the role of neuronal nitric oxide synthase (NOS1) in murine polymicrobial peritonitis and sepsis. DESIGN: Randomized experimental trial. SETTING: Animal research facility. SUBJECTS: B6129S NOS1+/+ and B6;129S4 NOS-/- mice. INTERVENTIONS:NOS1+/+ and NOS1-/- animals underwent cecal ligation and puncture (CLP) or sham surgery and received the NOS1 inhibitor 7-nitroindazole (7-NI) or vehicle. MEASUREMENTS AND MAIN RESULTS: After CLP, genetic deficiency and pharmacologic inhibition of NOS1 significantly increased risk of mortality [8.69 (3.27, 23.1), p<0.0001 and 1.71 (1.00, 2.92) p=0.05, hazard ratio of death (95% confidence interval) for NOS1-/- and 7-NI-treated NOS1+/+ respectively] compared with NOS1+/+ animals. In 7-NI-treated NOS1+/+ animals, there were increases (6 h) and then decreases (24 h), whereas in NOS-/- animals persistent increases in blood bacteria counts (p=0.04 for differing effects of 7-NI and NOS1-/-) were seen compared with NOS1(+/+) animals. After CLP, NOS1(-/-) had upregulation of inducible NOS and proinflammatory cytokines and greater increases in serum tumor necrosis factor-alpha and interleukin-6 levels compared with NOS1+/+ mice (all p<0.05). Following CLP, there were similar significant decreases in circulating leukocytes and lung lavage cells (p<or=0.0008) and significant increases in peritoneal lavage cells (p=0.0045) in all groups. Over 6 h and 24 h following CLP, compared with NOS1+/+, NOS-/- mice had significantly higher peritoneal cell concentrations {respectively 0.40+/-0.09 vs 0.79+/-0.15 [log(x10(4)cells/ml)] averaged over both times p=0.038}. CONCLUSIONS:Deficiency and inhibition of NOS1 increases mortality, possibly by increasing proinflammatory cytokine response and impairing bacterial clearance after CLP. These data suggest that NOS1 is important for survival, bacterial clearance, and regulation of cytokine response during infection and sepsis.
Authors: B D Freeman; Z Quezado; F Zeni; C Natanson; R L Danner; S Banks; M Quezado; Y Fitz; J Bacher; P Q Eichacker Journal: J Appl Physiol (1985) Date: 1997-11
Authors: H Togashi; M Sasaki; E Frohman; E Taira; R R Ratan; T M Dawson; V L Dawson Journal: Proc Natl Acad Sci U S A Date: 1997-03-18 Impact factor: 11.205
Authors: Perenlei Enkhbaatar; Kazunori Murakami; Katsumi Shimoda; Akio Mizutani; Roy McGuire; Frank Schmalstieg; Robert Cox; Hal Hawkins; Jeffery Jodoin; Steve Lee; Lillian Traber; David Herndon; Daniel Traber Journal: Am J Physiol Regul Integr Comp Physiol Date: 2003-05-22 Impact factor: 3.619
Authors: Julia Finkel; Virginia Guptill; Alfia Khaibullina; Nicholas Spornick; Olavo Vasconcelos; David J Liewehr; Seth M Steinberg; Zenaide M N Quezado Journal: Nitric Oxide Date: 2011-12-17 Impact factor: 4.427
Authors: Virginia Guptill; Xizhong Cui; Alfia Khaibullina; Jason M Keller; Nicholas Spornick; Andrew Mannes; Michael Iadarola; Zenaide M N Quezado Journal: Anesthesiology Date: 2011-05 Impact factor: 7.892
Authors: Kundan Solanki; Sajjan Rajpoot; Evgeny E Bezsonov; Alexander N Orekhov; Rohit Saluja; Anita Wary; Cassondra Axen; Kishore Wary; Mirza S Baig Journal: PeerJ Date: 2022-07-07 Impact factor: 3.061
Authors: Ion A Hobai; Emmanuel S Buys; Justin C Morse; Jessica Edgecomb; Eric H Weiss; Antonis A Armoundas; Xiuyun Hou; Alok R Khandelwal; Deborah A Siwik; Peter Brouckaert; Richard A Cohen; Wilson S Colucci Journal: Am J Physiol Heart Circ Physiol Date: 2013-08-09 Impact factor: 4.733
Authors: Karolina I Kulinska; Maria Billert; Krzysztof Sawinski; Katarzyna Czerniak; Michał Gaca; Krzysztof Kusza; Krzysztof W Nowak; Maria Siemionow; Hanna Billert Journal: Sci Rep Date: 2019-01-24 Impact factor: 4.379
Authors: Mahtab Moayeri; Devorah Crown; David W Dorward; Don Gardner; Jerrold M Ward; Yan Li; Xizhong Cui; Peter Eichacker; Stephen H Leppla Journal: PLoS Pathog Date: 2009-05-29 Impact factor: 6.823
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-01-04 Impact factor: 17.440